News >

Expert Covers Burgeoning Role of CAR T-Cell Therapy in Myeloma

Caroline Seymour
Published: Thursday, Apr 26, 2018

Maung Myo Htut, MD

Maung Myo Htut, MD
Chimeric antigen receptor (CAR) T-cell therapy has demonstrated potential for patients with relapsed/refractory multiple myeloma, and improvements in efficacy and safety may facilitate its transition into earlier-stage settings, says Maung Myo Htut, MD.

“At some point, it might replace the more targeted current standard of care, which is autologous stem cell transplant,” Htut explained.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication
x